Cantor Fitzgerald Forecasts Reduced Earnings for SI-BONE

SI-BONE, Inc. (NASDAQ:SIBN) – Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of SI-BONE in a note issued to investors on Tuesday, February 25th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of ($0.64) for the year, down from their previous forecast of ($0.19). Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $49.00 million for the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%.

Other analysts also recently issued reports about the stock. Needham & Company LLC raised their price objective on shares of SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday. Truist Financial reaffirmed a “buy” rating and set a $22.00 target price (up from $18.00) on shares of SI-BONE in a research note on Tuesday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $24.50.

SI-BONE Stock Up 1.7 %

Shares of SIBN stock opened at $18.12 on Thursday. The company has a market capitalization of $769.25 million, a price-to-earnings ratio of -19.70 and a beta of 1.17. SI-BONE has a one year low of $11.70 and a one year high of $19.16. The company’s fifty day moving average price is $16.11 and its 200-day moving average price is $14.79. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

Hedge Funds Weigh In On SI-BONE

Institutional investors and hedge funds have recently made changes to their positions in the business. Paradigm Capital Management Inc. NY boosted its stake in shares of SI-BONE by 5.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company’s stock worth $19,432,000 after purchasing an additional 69,831 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of SI-BONE by 8.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,666 shares of the company’s stock worth $1,439,000 after purchasing an additional 7,855 shares during the period. Virtus Fund Advisers LLC purchased a new position in shares of SI-BONE during the 4th quarter worth about $40,000. Virtus Investment Advisers Inc. purchased a new position in shares of SI-BONE during the 4th quarter worth about $196,000. Finally, Squarepoint Ops LLC purchased a new position in shares of SI-BONE during the 4th quarter worth about $449,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at SI-BONE

In other SI-BONE news, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total value of $51,013.00. Following the completion of the transaction, the insider now directly owns 222,814 shares of the company’s stock, valued at $3,097,114.60. This trade represents a 1.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the transaction, the chief financial officer now directly owns 189,319 shares of the company’s stock, valued at $2,633,427.29. The trade was a 2.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,311 shares of company stock valued at $130,356. Corporate insiders own 3.90% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.